RxDoctor Payments Data

Max Chikovsky, MD

Ophthalmology · Sarasota, FLNPI 1952832883

Payments from drug & device makers

$1,980in general payments, 2019–2025

Across 47 payments — averaging $42.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$659
  • AbbVie$299
  • Bausch & Lomb Americas Inc.$279
  • Mallinckrodt Hospital Products Inc.$143
  • ANI Pharmaceuticals, Inc.$127
  • Alimera Sciences, Inc.$111
  • plus $363 from 11 others

What the payments were for

  • Food & beverage$1,980100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,980 in reported general payments places this provider in the 45th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$155,994
Medicare patients
480
Services billed
3,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine282$214,120
LumiganBimatoprost102$57,598
XiidraLifitegrast41$35,265
RocklatanNetarsudil Mesylat/Latanoprost44$32,194
RhopressaNetarsudil Mesylate49$28,304
CombiganBrimonidine Tartrate/Timolol38$19,723
Cyclosporine42$14,719
Restasis MultidoseCyclosporine15$14,400
Latanoprost1,157$13,766
SimbrinzaBrinzolamide/Brimonidine Tart38$9,768
CequaCyclosporine16$8,964
Brimonidine Tartrate293$7,825
Prednisolone Acetate170$6,573
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat396$5,880
VyzultaLatanoprostene Bunod19$5,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Restasis Multidose$299$305,840437 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$40$60,49993 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$279$41,12760 claims
AlconSimbrinza$83$9,76838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →